PACIFIC — A Global Study to Assess the Effects of Durvalumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable NSCLC

Phase 3 · 2017 · Non-Small Cell Lung Cancer

Design

Randomized 2:1 to consolidation durvalumab vs placebo after definitive concurrent chemoradiation.

Population

Stage III unresectable NSCLC without progression after >=2 cycles of platinum-based concurrent chemoradiotherapy.

Primary Endpoint

progression-free survival (PFS) and overall survival (OS)

Key Result

PFS 16.8 vs 5.6 mo (HR 0.52); 5-yr OS 42.9% vs 33.4% (OS HR 0.72).

Guideline Impact

NCCN category 1 for consolidation after chemoradiation in unresectable stage III NSCLC